Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients with Advanced NSCLC with EGFR Exon 20 Insertions By Ogkologos - June 23, 2026 85 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the WU-KONG28 study Source RELATED ARTICLESMORE FROM AUTHOR Ovarian Reserve Better Indicator of Adjuvant Chemotherapy Benefit than Self-Reported Menopause Status, Age, or Other Hormone Levels Immune-Modulating SBRT Plus Anti-PD-L1 May Convert Immune-Cold ER-positive, HER2-negative EBC Into More Inflamed Tumours and Improve Response EMA Recommends Extension of Therapeutic Indications for Serplulimab MOST POPULAR The Opioid Epidemic and Cancer Pain Management: A Conversation with Dr.... July 16, 2018 FDA Proposes Rule Prohibiting Menthol Cigarettes June 27, 2022 How could proposed changes to data protection laws affect research? December 8, 2021 NICE recommends pembrolizumab for 1,600 more people with breast cancer November 14, 2022 Load more HOT NEWS Study Clarifies Timing of Immunotherapy for Advanced Bladder Cancer “Oncometabolite” Neutralizes Immune Cells Near Tumors Coronavirus reports – Part 8: “Going into hospital during this time... Talazoparib Plus Enzalutamide Improves rPFS in First-Line Treatment for Patients with...
